Key result
Ibrutinib increases atrial fibrillation risk, potentially driven by cardiac PI3K-Akt signaling inhibition.
Shows increased risk of atrial fibrillation in patients treated with ibrutinib, indicating potential cardiac side effects.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McMullen et al. (2014) studied this question. Ibrutinib increases the risk of atrial fibrillation, potentially through the inhibition of cardiac PI3K-Akt signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: